GlassScriptPhysician profile
Amir Abbasi
NPI 1871899922
$5,274.16
in general payments reported to CMS, 2019-2025
32 companies · $430 in 2025
The $430 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,634 · 2020: $112 · 2021: $675 · 2022: $995 · 2023: $759 · 2024: $668 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Liberty Surgical INC. | $1,424.00 | 2019 | |
| Organogenesis INC. | $807.55 | 2021-2025 | Puraply, Nushield, Via Matrix |
| Smith+Nephew, INC. | $686.35 | 2019-2024 | Grafix Pl, Stravix Pl, Regranex |
| Paratek Pharmaceuticals, INC. | $581.99 | 2021-2025 | Nuzyra |
| Convatec INC. | $494.06 | 2023-2025 | |
| Amgen INC. | $190.00 | 2024-2025 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $149.03 | 2019-2024 | Tapestry |
| Kerecis Limited | $142.97 | 2020-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Abbvie INC. | $131.90 | 2021-2024 | Dalvance |
| Nevro Corp. | $111.84 | 2021-2022 | |
| Paladin Technology Solutions | $57.02 | 2023-2024 | |
| Nabriva Therapeutics, Plc | $51.71 | 2021-2022 | |
| Paragon 28, INC. | $38.13 | 2021-2022 | |
| Ibsa Pharma INC. | $36.53 | 2021-2024 | Tirosint, Licart |
| Acumed LLC | $31.10 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $26.67 | 2025 | Activ.A.C. |
| Integra Lifesciences Corporation | $26.35 | 2021 | |
| Livanova USA, INC. | $25.96 | 2022 | |
| Zyla Life Sciences, INC. | $25.71 | 2019 | |
| Orthofix Medical, INC. | $24.69 | 2024 | Physio-Stim |
| Lifenet Health | $23.20 | 2023 | |
| Grt US Holding, INC. | $22.94 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.72 | 2022 | |
| Stryker Corporation | $20.39 | 2022 | |
| Horizon Therapeutics Plc | $19.33 | 2023 | Krystexxa |
| Progenacare Global, LLC | $18.26 | 2023 | |
| Averitas Pharma INC. | $17.45 | 2025 | Qutenza |
| Biotissue Holdings INC. | $15.94 | 2022 | |
| Treace Medical Concepts, INC. | $15.66 | 2025 | |
| Bioventus LLC | $14.83 | 2022 | |
| Anika Therapeutics, INC. | $12.80 | 2022 | |
| Biocomposites INC | $7.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.